Experimental Studies

Dr. Nadim Mahmud

Study Design · Research Curriculum

Randomized controlled trials are the gold standard for establishing causality. This module covers the anatomy of an RCT, how randomization and blinding work, how to interpret different analysis strategies, and when pragmatic or non-randomized designs are more appropriate.

Introduction

Among all research study designs, the randomized controlled trial (RCT) holds a privileged position. It is the only design capable of controlling for both known and unknown confounders simultaneously, and it is therefore the strongest design for establishing a causal relationship between an intervention and an outcome.

The logic of the RCT is elegant: if participants are randomly assigned to an intervention or control group, the only systematic difference between the groups should be the intervention itself. Any difference in outcomes that emerges over time can therefore be attributed to the intervention rather than to pre-existing differences between groups.

Why does randomization matter so much? In an observational study, sicker patients may be more (or less) likely to receive a treatment - making it difficult to separate the effect of the treatment from the effect of the underlying disease. Randomization breaks that link. When done correctly, treated and untreated groups are comparable at baseline, and any outcome difference is interpretable as a treatment effect.

That said, RCTs are not always the right tool. They are expensive, time-consuming, and ethically impossible in some circumstances. Understanding not just how RCTs work but when they are and are not appropriate is essential for designing and critically appraising clinical research.

Overview of Research Study Designs

Experimental studies sit within the analytic branch of the study design hierarchy. The defining feature of experimental designs is that the investigator assigns the exposure or intervention - in contrast to observational studies, where the investigator simply observes. Click any node in the Experimental branch to learn more.

Research Study Designs

Descriptive

Case Reports · Case Series

Analytic

Evaluates exposure-outcome associations

Experimentalfocus

Observational

Cohort · Case-Control · Cross-Sectional

Click a study type to learn more

Experimental vs. Observational: In an RCT, the investigator controls who receives the intervention. In an observational study, exposures occur naturally and the investigator measures them. This distinction determines whether causal inference is valid.

Anatomy of an RCT

Every RCT contains the same core structural elements. Understanding these elements lets you read any trial paper systematically, identify potential sources of bias, and assess the validity of the conclusions.

Population (P): The target population from which participants are recruited. Defined by inclusion and exclusion criteria. Strict criteria increase internal validity but reduce generalizability.

Randomization: Random allocation of participants to intervention or control groups. The key mechanism for eliminating confounding. Must be truly random - not alternating, not by day of the week.

Intervention (I): The exposure under study: a drug, procedure, device, behavioral change, or other manipulation. Should be clearly specified in the protocol.

Control (C): The comparator group: placebo, usual care, or active comparator. Choice of control strongly influences the clinical relevance of trial results.

Outcome (O): The endpoint used to measure the effect of the intervention. Primary outcome should be pre-specified. Hard clinical endpoints (mortality, hospitalization) are more meaningful than surrogate endpoints (lab values, imaging findings).

Follow-up: The duration over which participants are observed after randomization. Loss to follow-up can introduce bias if it is differential across groups.

Analysis: Pre-specified statistical approach. The primary analysis is almost always intent-to-treat (ITT). Sample size calculation should be reported with the target effect size and acceptable error rates.

Randomization

Randomization is what separates an RCT from all other study designs. Its purpose is to create two groups that are equivalent at baseline so that any subsequent difference in outcomes can be attributed to the intervention. Randomization controls for confounders - both measured and unmeasured.

Types of Randomization

Simple Randomization

Each participant is assigned independently with a fixed probability (e.g., a coin flip). Simple and truly random, but can result in unequal group sizes by chance, particularly in small trials.

Best for: large trials where small imbalances are unlikely to matter

Block Randomization

Participants are randomized in blocks of a fixed size (e.g., blocks of 4: AABB, ABAB, ABBA, etc.) to ensure roughly equal group sizes at all times. Particularly important if the trial may be stopped early.

Best for: ensuring balanced groups at interim analyses

Stratified Randomization

Randomization occurs within predefined subgroups (strata) defined by key prognostic variables (e.g., age, disease severity, study site). Ensures balance on the most important potential confounders.

Best for: trials where imbalance in a key variable would be problematic

Cluster Randomization

Groups (clusters) rather than individuals are randomized. For example, hospitals, clinics, or schools are assigned to intervention or control. Used when individual randomization is impractical or would lead to contamination.

Best for: interventions delivered at the group level (e.g., hospital protocols, educational programs)

Allocation Concealment

Allocation concealment is distinct from randomization. It refers to hiding the allocation sequence from investigators at the time of enrollment, before a participant is assigned. Without concealment, an investigator who knows the next assignment (e.g., "the next participant gets drug A") may selectively enroll or exclude patients, introducing selection bias before the trial even begins.

Common confusion: Allocation concealment and blinding are not the same thing. Allocation concealment prevents foreknowledge of group assignment during enrollment (before randomization). Blinding prevents knowledge of group assignment during follow-up (after randomization). Both are important, but they address different threats to validity.

Methods for allocation concealment

Sequentially numbered, opaque, sealed envelopes (SNOSE)
Centralized computer-based randomization system (most secure)
Pharmacy-controlled randomization (drug is dispensed directly from pharmacy)

Blinding

Blinding (also called masking) refers to concealing the treatment assignment from one or more parties involved in the trial after randomization. Its purpose is to prevent knowledge of group assignment from influencing behavior, assessment, or outcomes.

Open-label (Unblinded)

Who is blinded: All parties - participants, clinicians, and outcome assessors - know the treatment assignment.

Typical use: Surgical vs. medical interventions; behavioral interventions; infeasible to blind due to the nature of the treatment

Bias implications: Performance bias (providers alter care), detection bias (outcome assessors influenced by assignment), response bias (participants report outcomes differently)

Single-Blind

Who is blinded: One party (typically the participant) is blinded to treatment assignment.

Typical use: When blinding investigators is impractical but patient-reported outcomes are a primary concern

Bias implications: Investigator behavior is unblinded; potential for performance and detection bias

Double-Blind

Who is blinded: Both participants and the investigators administering treatment (and often outcome assessors) are blinded.

Typical use: Drug trials with placebo control; the standard for most pharmaceutical RCTs

Bias implications: Minimizes most performance and detection bias; unblinding can still occur due to side effect profiles

Triple-Blind

Who is blinded: Participants, investigators, and the data safety monitoring board (or statisticians analyzing the data) are all blinded.

Typical use: High-stakes trials where even the data analysts should not know group assignment during interim reviews

Bias implications: Maximal protection against bias; most resource-intensive; rarely necessary

Reading a trial methods section: When a paper says "double-blind," confirm who is actually blinded by reading the methods. The term is applied inconsistently in the literature. The key question is whether the outcome assessors were blinded - if they were not, detection bias is a real concern regardless of whether patients were blinded.

Trial Phases (I-IV)

Drug and device development proceeds through a formal sequence of trial phases, each designed to answer progressively more complex questions before a therapy reaches widespread use. Understanding the phases helps you interpret what a trial can and cannot tell you.

›

Click a phase to expand details

On Phase II interpretation: A positive Phase II result is not the same as evidence of efficacy. Phase II trials are powered for signal detection, not definitive conclusions. Many drugs that "succeed" in Phase II fail in Phase III. When a Phase II trial makes headlines, it warrants cautious enthusiasm rather than a change in practice.

Intent-to-Treat vs. Per-Protocol Analysis

In any trial, some participants will not receive the treatment they were assigned to - due to withdrawal, side effects, crossover, or protocol deviations. How these participants are handled in the analysis has major implications for the validity of the results.

Best practice: A well-reported RCT presents both ITT and per-protocol analyses. If they agree, confidence in the findings is higher. If they diverge, the authors should explain why and which is more appropriate given the research question.

Pragmatic vs. Explanatory Trials

Not all RCTs are designed to answer the same question. The explanatory trial asks "does this intervention work under ideal, controlled conditions?" while the pragmatic trial asks "does this intervention work in the real world, for patients in routine clinical practice?"

These two trial types represent opposite ends of a spectrum (formalized in the PRECIS-2 framework) and differ across multiple design dimensions. Most trials fall somewhere in between.

Dimension	Explanatory Trial	Pragmatic Trial
Primary question	Does the intervention work under ideal conditions?	Does the intervention work in real-world practice?
Eligibility criteria	Narrow; excludes comorbidities, polypharmacy, non-adherence	Broad; inclusive of typical clinical patients
Setting	Academic centers; controlled environment	Community hospitals, primary care, diverse sites
Intervention	Standardized; strict protocol adherence monitored	Flexible; delivered as it would be in practice
Control	Placebo or active comparator	Usual care or best available alternative
Outcomes	Surrogate or mechanistic endpoints; short-term	Clinical or patient-reported outcomes; often long-term
Blinding	Often double-blind	Often open-label (difficult to blind real-world interventions)
Generalizability	Lower (internal validity prioritized)	Higher (external validity prioritized)

Efficacy vs. Effectiveness: Explanatory trials measure efficacy (can it work?); pragmatic trials measure effectiveness (does it work in practice?). Both questions matter. A drug that works under ideal conditions but shows no benefit in pragmatic trials may face implementation barriers, adherence issues, or benefit only a subgroup of patients.

Non-Randomized Experimental Designs

Not all experimental studies involve randomization. When randomization is impractical, unethical, or impossible, investigators may use a quasi-experimental design in which they assign an intervention but participants are not randomized. These designs retain one key feature of the RCT - the investigator controls who receives the intervention - but lack the confounding control that randomization provides.

Interrupted Time Series (ITS)

Outcomes are measured at multiple time points before and after an intervention is introduced to a population. The intervention is applied to all participants at a defined moment. Strength depends on pre-intervention trend stability.

Example: measuring C. difficile rates at 12 months before and after implementation of a hospital-wide antibiotic stewardship program.

Before-After Study

Outcomes in the same participants (or the same unit) are compared before and after an intervention is introduced. Simpler than ITS, but highly susceptible to confounding from concurrent changes in practice or patient population.

Example: comparing 30-day readmission rates before vs. after implementation of a new discharge protocol.

Difference-in-Differences

Compares the change in outcomes over time in an intervention group vs. a concurrent control group that did not receive the intervention. Controls for time trends common to both groups, making it more robust than a simple before-after comparison.

Common in health policy research examining the effect of policy changes.

Stepped-Wedge Design

All clusters eventually receive the intervention, but they are randomized to when they cross over from control to intervention. Useful when it would be unethical or impractical to permanently withhold a beneficial intervention from some clusters.

Common in quality improvement, health systems, and global health research.

Evidence hierarchy: Non-randomized experimental studies are subject to confounding in ways that RCTs are not. They occupy a higher tier than purely observational studies (because the investigator controls the exposure) but a lower tier than RCTs (because groups may differ at baseline). Interpret their results with appropriate caution.

When RCTs Fall Short

The RCT is the strongest design for causal inference, but it is not always the right tool. Understanding its limitations prevents the reflexive dismissal of observational evidence and helps you recognize when RCT evidence genuinely exists and when it does not.

Ethical infeasibility

You cannot randomize participants to smoke, withhold a proven therapy, or assign a harmful exposure. Many of the most important questions in medicine - the effects of smoking, the benefit of surgery in emergency settings, the role of childhood nutrition - cannot be addressed with RCTs for ethical reasons.

Rare outcomes and long latency periods

RCTs are poorly suited to studying rare outcomes or outcomes that take decades to develop. A trial designed to detect a 20% reduction in a 1-in-10,000 event would require enormous sample sizes and follow-up durations that are not feasible.

Limited generalizability

Strict eligibility criteria mean that RCT populations often differ from real-world patients (older, more comorbidities, polypharmacy). The effect size observed in a trial may not replicate in clinical practice - a problem that pragmatic trials are designed to address.

Cost and feasibility

Phase III RCTs routinely cost hundreds of millions of dollars and take years to complete. Many clinically important questions will never have RCT data simply because funding and infrastructure are unavailable.

Patient preference and crossover

In trials of invasive procedures or lifestyle interventions, many patients refuse randomization or cross over between arms. High crossover rates dilute the treatment effect in ITT analyses and complicate per-protocol analyses.

A note on evidence hierarchies: The evidence hierarchy places RCTs above observational studies, but this does not mean observational evidence is worthless. For many questions, high-quality observational data from large populations are the best evidence we have. The key is understanding what each design can and cannot tell you, and interpreting results accordingly.

Interactive Quiz

Read each scenario and select the best answer before revealing the explanation. These questions are designed to test your understanding of trial design, blinding, and analysis strategies.

A pharmaceutical company is enrolling 12 patients with treatment-refractory melanoma to receive escalating doses of a new checkpoint inhibitor. The primary endpoints are maximum tolerated dose and dose-limiting toxicities. No placebo group is included.

Investigators design a trial of a new beta-blocker for heart failure. Participants are randomized 1:1 to the drug or placebo. All patients, treating physicians, and outcome assessors are unaware of group assignment. The primary endpoint is 30-day all-cause mortality.

The PIONEER trial randomizes 5,000 patients with atrial fibrillation across 200 community hospitals and academic centers to one of two anticoagulation regimens. Patients with prior stroke, renal failure, or a CHADS2 score below 2 are excluded, but otherwise enrollment is intentionally broad. The intervention is administered per the treating clinician's judgment. The primary outcome is stroke or systemic embolism at 2 years.

In a completed RCT comparing two antihypertensive drugs, 18% of patients assigned to Drug A discontinued the medication due to side effects and were switched to Drug B. The primary analysis counts all 18% in the Drug A group based on their original assignment. A secondary analysis excludes all patients who switched drugs or had major protocol deviations.

Continue Learning

With observational and experimental designs covered, the next step is understanding how descriptive research fits into the picture - and why case reports and case series remain a valuable entry point for trainee researchers.

Related Module

Observational Studies

Review cohort, case-control, and cross-sectional designs - and how they compare with the RCT.

Explore →

Up Next

Descriptive Studies

Learn how case reports and case series fit into the research landscape, and how to write one that will get published.

Explore →